CPA welcomed the U.S. Department of War expanding its Section 1260H list of Chinese military companies and praised recent efforts by lawmakers, including Senator Rick Scott (R-FL), to draw greater attention to the threat posed by China’s military-civil fusion strategy.
For too long, foreign actors with no real U.S. presence have been able to import into the American market while shielding themselves from the duties, penalties, and laws that domestic producers and legitimate U.S. importers must obey. The order takes aim squarely at that imbalance.
Without secure upstream API and 6-APA production, the United States does not have true antibiotic supply security. With the right policy framework and close coordination with European partners, we can rebuild domestic capacity, strengthen allied production, and secure essential medicines for the long term.
The findings reinforce a persistent pattern in global solar trade: when enforcement actions target specific countries, production and shipments shift to new jurisdictions.
Revoking PNTR for China would move Chinese imports onto an average effective Column 2 tariff rate of 38.9 percent, helping rebalance trade, restore domestic production capacity, and reduce strategic dependence on an increasingly adversarial economic system.
CPA welcomes new proposals from the Food and Drug Administration (FDA) aimed at rebuilding domestic generic drug manufacturing, strengthening oversight of foreign pharmaceutical production, and improving supply chain transparency.
